BIOPHYTIS Identifies False Report Regarding COVA study
BIOPHYTIS SA (NasdaqCM: BPTS) addressed a false report regarding its COVA study for Sarconeos (BIO101) in COVID-19, which was disseminated without its consent. The misleading information was circulated by unknown sources, prompting the company to notify relevant authorities. As per the latest updates, an independent Data Monitoring Committee (DMC) provided a favorable opinion on the safety of Sarconeos following an interim analysis of 50 participants in the study. BIOPHYTIS focuses on therapeutics for age-related diseases, with Sarconeos being developed for conditions like sarcopenia and severe respiratory symptoms of COVID-19.
- Independent DMC provided a favorable opinion on Sarconeos' safety for COVID-19 patients following interim analysis.
- Sarconeos is involved in multiple clinical trials targeting severe respiratory manifestations of COVID-19.
- A false report regarding the COVA study could damage trust and investor confidence.
- The company's reputation may be negatively affected by the unauthorized release of misleading information.
PARIS and CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, has been made aware of a false report regarding the status of its COVA study of its Sarconeos (BIO101) treatment in COVID-19 in Brazil. On April 12, 2021, an article was released via WBOC unbeknownst to BIOPHYTIS. The press release was misleading and released without BIOPHYTIS’ knowledge by unknown sources.
BIOPHYTIS did not write, release nor approve this press release, on the subject of the COVA study in Brazil. BIOPHYTIS has reported this instance to the proper authorities and WBOC. BIOPHYTIS disclaims any responsibility arising out of or in connection with this press release.
The most recent news on the COVA trial is that the independent Data Monitoring Committee (DMC) delivered a favorable opinion on the safety of Sarconeos (BIO101) in patients infected with COVID-19, following the scheduled interim analysis of the 50 participants from Part 1 of the study. This press release, dated March 22, 2021, can be read here.
About BIOPHYTIS
BIOPHYTIS SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information visit www.biophytis.com
BIOPHYTIS Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com
Media contact
Life Sci Advisors
Sophie Baumont/Chris Maggos
sophie@lifesciadvisors.com
T: +33 6 27 74 74 49
FAQ
What is the status of the COVA study for Sarconeos (BPTS)?
When was the false report about the COVA study released?
How did BIOPHYTIS respond to the false report?
What is Sarconeos (BPTS) being developed for?
What are the clinical trials associated with Sarconeos (BPTS)?
